This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2007 Oct;178(4 Pt 1):1148.

doi: 10.1016/j.juro.2007.07.066. Epub 2007 Aug 14.

Androgen deprivation therapy for prostate cancer

PMID: 17698142
DOI: 10.1016/j.juro.2007.07.066

Editorial

Androgen deprivation therapy for prostate cancer

Robert Bahnson. J Urol. 2007 Oct.

. 2007 Oct;178(4 Pt 1):1148.

doi: 10.1016/j.juro.2007.07.066. Epub 2007 Aug 14.

Author

PMID: 17698142
DOI: 10.1016/j.juro.2007.07.066

No abstract available

PubMed Disclaimer

Comment on

Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.
Morote J, Orsola A, Planas J, Trilla E, Raventós CX, Cecchini L, Catalán R. Morote J, et al. J Urol. 2007 Oct;178(4 Pt 1):1290-5. doi: 10.1016/j.juro.2007.05.129. Epub 2007 Aug 14. J Urol. 2007. PMID: 17698136
Health care cost associated with prostate cancer, androgen deprivation therapy and bone complications.
Krupski TL, Foley KA, Baser O, Long S, Macarios D, Litwin MS. Krupski TL, et al. J Urol. 2007 Oct;178(4 Pt 1):1423-8. doi: 10.1016/j.juro.2007.05.135. Epub 2007 Aug 16. J Urol. 2007. PMID: 17706711

Similar articles

Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect.
Ross RW, Xie W, Regan MM, Pomerantz M, Nakabayashi M, Daskivich TJ, Sartor O, Taplin ME, Kantoff PW, Oh WK. Ross RW, et al. Cancer. 2008 Mar 15;112(6):1247-53. doi: 10.1002/cncr.23304. Cancer. 2008. PMID: 18293426 Clinical Trial.
[Complete hormonal block vs. simple hormonal block in the treatment of carcinoma of the prostate].
Berenguer Sánchez A. Berenguer Sánchez A. Arch Esp Urol. 2002 Sep;55(7):771-5. Arch Esp Urol. 2002. PMID: 12380304 Spanish. No abstract available.
Role of testosterone in managing advanced prostate cancer.
Rove KO, Debruyne FM, Djavan B, Gomella LG, Koul HK, Lucia MS, Petrylak DP, Shore ND, Stone NN, Crawford ED. Rove KO, et al. Urology. 2012 Oct;80(4):754-62. doi: 10.1016/j.urology.2012.05.006. Epub 2012 Jul 13. Urology. 2012. PMID: 22795376 Review.
Serum testosterone level to predict the efficacy of sequential use of antiandrogens as second-line treatment following androgen deprivation monotherapy in patients with castration-resistant prostate cancer.
Hashimoto K, Masumori N, Hashimoto J, Takayanagi A, Fukuta F, Tsukamoto T. Hashimoto K, et al. Jpn J Clin Oncol. 2011 Mar;41(3):405-10. doi: 10.1093/jjco/hyq193. Epub 2010 Oct 14. Jpn J Clin Oncol. 2011. PMID: 20947624
[New aspects of anti-androgenic therapy of prostatic cancer].
Portnoĭ AS. Portnoĭ AS. Urol Nefrol (Mosk). 1985 May-Jun;(3):69-73. Urol Nefrol (Mosk). 1985. PMID: 3892832 Review. Russian. No abstract available.

See all similar articles

Cited by

Selective androgen receptor modulators in preclinical and clinical development.
Narayanan R, Mohler ML, Bohl CE, Miller DD, Dalton JT. Narayanan R, et al. Nucl Recept Signal. 2008;6:e010. doi: 10.1621/nrs.06010. Epub 2008 Nov 26. Nucl Recept Signal. 2008. PMID: 19079612 Free PMC article. Review.
Effect of aberrantly methylated androgen receptor target gene PCDH7 on the development of androgen-independent prostate cancer cells.
Xu S, Wu X, Tao Z, Li H, Fan C, Chen S, Guo J, Ning Y, Hu X. Xu S, et al. Genes Genomics. 2020 Mar;42(3):299-307. doi: 10.1007/s13258-019-00903-w. Epub 2019 Dec 23. Genes Genomics. 2020. PMID: 31872382
Comparison on efficacy of radical prostatectomy versus external beam radiotherapy for the treatment of localized prostate cancer.
Chen L, Li Q, Wang Y, Zhang Y, Ma X. Chen L, et al. Oncotarget. 2017 Aug 9;8(45):79854-79863. doi: 10.18632/oncotarget.20078. eCollection 2017 Oct 3. Oncotarget. 2017. PMID: 29108367 Free PMC article.
Non-THC cannabinoids inhibit prostate carcinoma growth in vitro and in vivo: pro-apoptotic effects and underlying mechanisms.
De Petrocellis L, Ligresti A, Schiano Moriello A, Iappelli M, Verde R, Stott CG, Cristino L, Orlando P, Di Marzo V. De Petrocellis L, et al. Br J Pharmacol. 2013 Jan;168(1):79-102. doi: 10.1111/j.1476-5381.2012.02027.x. Br J Pharmacol. 2013. PMID: 22594963 Free PMC article.
Inhibition of human tumour prostate PC-3 cell growth by cannabinoids R(+)-Methanandamide and JWH-015: involvement of CB2.
Olea-Herrero N, Vara D, Malagarie-Cazenave S, Díaz-Laviada I. Olea-Herrero N, et al. Br J Cancer. 2009 Sep 15;101(6):940-50. doi: 10.1038/sj.bjc.6605248. Epub 2009 Aug 18. Br J Cancer. 2009. PMID: 19690545 Free PMC article.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information